Market Cap 171.99M
Revenue (ttm) 240.47M
Net Income (ttm) 11.41M
EPS (ttm) N/A
PE Ratio 10.71
Forward PE N/A
Profit Margin 4.74%
Debt to Equity Ratio 0.97
Volume 9,200
Avg Vol 11,648
Day's Range N/A - N/A
Shares Out 2.95M
Stochastic %K 53%
Beta 0.70
Analysts Hold
Price Target N/A

Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments: Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other g...

Industry: Furnishings, Fixtures & Appliances
Sector: Consumer Cyclical
Phone: 704 873 7202
Address:
2700 West Front Street, PO.Box 1842, Statesville, United States
seekingyield1
seekingyield1 Jul. 11 at 1:08 AM
$KEQU now 35% tariffs on the competition. Going to be quite a year https://www.bloomberg.com/news/articles/2025-07-11/trump-to-impose-35-tariff-on-goods-from-canada-mcy2ve5f
0 · Reply
seekingyield1
seekingyield1 Jul. 9 at 7:24 PM
$KEQU now a bit over 6x EPS
0 · Reply
d_risk
d_risk Jul. 5 at 3:16 AM
$KEQU - Kewaunee Scientific Corporation Common Stock - 10K - Updated Risk Factors KEQU’s 2025 10-K shows reduced sales concentration risk, removal of operational and IT risks, new risks from Nu Aire acquisition including SOX compliance and goodwill impairment, broader geopolitical and regulatory risks, and exposure to shifting U.S. trade policies. #ScientificInstruments #TradePolicy #GeopoliticalRisks #SOXCompliance #AcquisitionRisks 🟢 Added 🟠 Removed https://d-risk.ai/KEQU/10-K/2025-07-02
0 · Reply
d_risk
d_risk Jul. 3 at 2:46 AM
$KEQU - Kewaunee Scientific Corporation Common Stock - 10K - Updated Risk Factors KEQU’s 2025 10-K shows reduced sales concentration risk, removal of operational and IT risks, new risks from Nu Aire acquisition including SOX compliance and goodwill impairment, broader geopolitical and regulatory risks, and exposure to shifting U.S. trade policies. #ScientificInstruments #TradePolicy #GeopoliticalRisks #SOXCompliance #AcquisitionRisks 🟢 Added 🟠 Removed https://d-risk.ai/KEQU/10-K/2025-07-02
0 · Reply
seekingyield1
seekingyield1 Jul. 2 at 3:03 PM
$KEQU 10K now out - free cash flow came out to a solid ~$9M on the Q. More interesting are the NuAire stats: Nuaire revenue on the Q was $19.5m and profit was ~700k - so the bulk of this monster quarter was simply the core KEQU businesses, with NuAire accounting for under 20% of net income despite being over 25% of revenue for the Q. Pre-acquisition NuAire was running well over $1M/Q (is a higher margin business than KEQU historically) so as the normal disruptions from acquisition settle there is significant upside, let alone synergies that may be realized Currently trading at ~6x EPS and ~4x EBITDA which are at surprisingly depressed levels
1 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 5:40 PM
$KEQU just exploded 47% — here’s why it matters 👀 Q4 and FY25 results beat estimates, with sales jumping and the Nu Aire acquisition fueling growth momentum. Full breakdown of the move here 👉 https://www.zacks.com/stock/news/2558108/kewaunee-scientific-stock-soars-47-after-q4-earnings-beat-estimates?cid=sm-stocktwits-2-2558108-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2558108_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 4:24 PM
$KEQU up 47.1% since Q4 results — what's driving the surge? 🚀 🔥 Q4 net sales soared 36.1% to $77.1M 📈 Adjusted EPS up 25.8% to $1.95 💼 Domestic sales jump 54.7%, aided by Nu Aire acquisition Discover what's powering KEQU's impressive performance 👉 https://www.zacks.com/commentary/2558108/kewaunee-scientific-stock-soars-47-after-q4-earnings-beat-estimates?cid=sm-stocktwits-2-2558108-body-451&ADID=SYND_STOCKTWITS_TWEET_2_2558108_BODY_451
0 · Reply
seekingyield1
seekingyield1 Jun. 30 at 1:34 PM
$KEQU a reason for the oddly low priced sales earlier this year may have been April taxes, but may also have been due to some share grants that would be happening now. I think any concern over lack of aligned incentives are now gone - Hull has over 25k shares (current value $1.5m) vesting over the next three years upon the achievement of his goals. Gardner has ~10k
0 · Reply
seekingyield1
seekingyield1 Jun. 27 at 6:07 PM
$KEQU the primary competitor, Ontario based Mott, continues to be an unappealing option as Canada trade talks implode https://www.bloomberg.com/news/articles/2025-06-27/trump-cuts-off-trade-talks-with-canada-threatens-to-set-tariff
0 · Reply
seekingyield1
seekingyield1 Jun. 27 at 2:26 PM
$KEQU now trades at ~6x EPS and ~4x EBITDA
0 · Reply
Latest News on KEQU
Kewaunee Scientific's Share Price Hasn't Caught Up To Results

Dec 18, 2023, 7:17 PM EST - 1 year ago

Kewaunee Scientific's Share Price Hasn't Caught Up To Results


seekingyield1
seekingyield1 Jul. 11 at 1:08 AM
$KEQU now 35% tariffs on the competition. Going to be quite a year https://www.bloomberg.com/news/articles/2025-07-11/trump-to-impose-35-tariff-on-goods-from-canada-mcy2ve5f
0 · Reply
seekingyield1
seekingyield1 Jul. 9 at 7:24 PM
$KEQU now a bit over 6x EPS
0 · Reply
d_risk
d_risk Jul. 5 at 3:16 AM
$KEQU - Kewaunee Scientific Corporation Common Stock - 10K - Updated Risk Factors KEQU’s 2025 10-K shows reduced sales concentration risk, removal of operational and IT risks, new risks from Nu Aire acquisition including SOX compliance and goodwill impairment, broader geopolitical and regulatory risks, and exposure to shifting U.S. trade policies. #ScientificInstruments #TradePolicy #GeopoliticalRisks #SOXCompliance #AcquisitionRisks 🟢 Added 🟠 Removed https://d-risk.ai/KEQU/10-K/2025-07-02
0 · Reply
d_risk
d_risk Jul. 3 at 2:46 AM
$KEQU - Kewaunee Scientific Corporation Common Stock - 10K - Updated Risk Factors KEQU’s 2025 10-K shows reduced sales concentration risk, removal of operational and IT risks, new risks from Nu Aire acquisition including SOX compliance and goodwill impairment, broader geopolitical and regulatory risks, and exposure to shifting U.S. trade policies. #ScientificInstruments #TradePolicy #GeopoliticalRisks #SOXCompliance #AcquisitionRisks 🟢 Added 🟠 Removed https://d-risk.ai/KEQU/10-K/2025-07-02
0 · Reply
seekingyield1
seekingyield1 Jul. 2 at 3:03 PM
$KEQU 10K now out - free cash flow came out to a solid ~$9M on the Q. More interesting are the NuAire stats: Nuaire revenue on the Q was $19.5m and profit was ~700k - so the bulk of this monster quarter was simply the core KEQU businesses, with NuAire accounting for under 20% of net income despite being over 25% of revenue for the Q. Pre-acquisition NuAire was running well over $1M/Q (is a higher margin business than KEQU historically) so as the normal disruptions from acquisition settle there is significant upside, let alone synergies that may be realized Currently trading at ~6x EPS and ~4x EBITDA which are at surprisingly depressed levels
1 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 5:40 PM
$KEQU just exploded 47% — here’s why it matters 👀 Q4 and FY25 results beat estimates, with sales jumping and the Nu Aire acquisition fueling growth momentum. Full breakdown of the move here 👉 https://www.zacks.com/stock/news/2558108/kewaunee-scientific-stock-soars-47-after-q4-earnings-beat-estimates?cid=sm-stocktwits-2-2558108-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2558108_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 30 at 4:24 PM
$KEQU up 47.1% since Q4 results — what's driving the surge? 🚀 🔥 Q4 net sales soared 36.1% to $77.1M 📈 Adjusted EPS up 25.8% to $1.95 💼 Domestic sales jump 54.7%, aided by Nu Aire acquisition Discover what's powering KEQU's impressive performance 👉 https://www.zacks.com/commentary/2558108/kewaunee-scientific-stock-soars-47-after-q4-earnings-beat-estimates?cid=sm-stocktwits-2-2558108-body-451&ADID=SYND_STOCKTWITS_TWEET_2_2558108_BODY_451
0 · Reply
seekingyield1
seekingyield1 Jun. 30 at 1:34 PM
$KEQU a reason for the oddly low priced sales earlier this year may have been April taxes, but may also have been due to some share grants that would be happening now. I think any concern over lack of aligned incentives are now gone - Hull has over 25k shares (current value $1.5m) vesting over the next three years upon the achievement of his goals. Gardner has ~10k
0 · Reply
seekingyield1
seekingyield1 Jun. 27 at 6:07 PM
$KEQU the primary competitor, Ontario based Mott, continues to be an unappealing option as Canada trade talks implode https://www.bloomberg.com/news/articles/2025-06-27/trump-cuts-off-trade-talks-with-canada-threatens-to-set-tariff
0 · Reply
seekingyield1
seekingyield1 Jun. 27 at 2:26 PM
$KEQU now trades at ~6x EPS and ~4x EBITDA
0 · Reply
Bruces4
Bruces4 Jun. 27 at 2:08 PM
$KEQU Great call!
0 · Reply
Esau815
Esau815 Jun. 27 at 12:07 PM
$KEQU Thanks Yield for the information. I ran some competitive information through AI and indeed Mott does show up. Estimate that US Lab sales are $1.5B of which KEQU's $177MM would make up about 12%. (Obviously rough numbers). Not sure whether estimates include installation or not which of course KEQU no longer does. Obviously, the Q was an absolute Mt. Etna blow out. And agree with you that there is no seasonality and we can extrapolate the $10MM EBITDA to $40MM. Biggest concern for me is whether that backlog holds. University budgets are being destroyed by Orange Man. Lab space glut in Boston. The arrows SEEM to be pointing down--way down--but Hull's comments remain optimistic. On the upside? (Or downside?) We need more time to see NuAire impact. Things look good for now. Given 11/24 deal closed? KEQU is already about 1/5 done paying off the family portion of that debt.
1 · Reply
satsandstocks
satsandstocks Jun. 27 at 1:54 AM
$KEQU strong earnings gapper!!
0 · Reply
seekingyield1
seekingyield1 Jun. 26 at 7:58 PM
$KEQU to put this move into context, last December (FQ2) the stock made an almost identical move from ~$43 --> $54 when EPS sequentially went from $0.93 to $1.42. At that time it seemed like ~$6 in EPS would be obtainable over time and the stock continued to ~$70 - a bit over 10x eps potential This quarter EPS has sequentially gone from $1.09 to $1.95, a higher jump from a higher base, and with the transaction now pretty much in the rear view the sustainability of this EPS is increasingly likely. The EBITDA, below, is much more dramatic - because interest expense post transaction is significant the real earnings potential of this is obscured. Absent interest expense EPS is well over $2.50 a quarter, and as they pay down debt EPS will formulaically rise Seems crazy to buy a stock up 35%, but you can understand why nobody is selling something trading at an unlevered ~5x EPS with a clear path to that unlevering and incremental operating leverage incoming
2 · Reply
Esau815
Esau815 Jun. 26 at 6:06 PM
$KEQU Agree with Seeking Yield about most issues--especially about getting OpEx synergies. From what I've been told: (1) KEQU sales takes place with huge lead times while (2) NuAire sales are more "just in time". I've heard that there there will be challenges getting these competing schedules to coordinate. The bigger risk to me is whether that backlog holds up. Trump has eviscerated science (among other things). How is there growing demand for what they provide? The other risk short term is if Tom and Don decide once again to sell stock. Know that it doesn't impact the company's fundamentals. But additional sales would certainly douse the flames of momentum that is today.
1 · Reply
topstockalerts
topstockalerts Jun. 26 at 4:57 PM
Top Gainers PT2 $ADIL $BIAF $SRFM $KEQU $CRML
0 · Reply
seekingyield1
seekingyield1 Jun. 26 at 4:41 PM
$KEQU this is a great quarter. Given there is no seasonality in this business it is fair to annualize a quarter to at least see earnings potential (despite some significant transaction related volatility impacting EPS the past few), and ~$2 in EPS for the quarter annualizes to ~$8 for the year implying at ~7x EPS multiple here even after this rise. The stock was priced as a levered busted acquirer over the past couple of months as questions about the NuAire transaction developed, and now they are posting all time high EPS and EBITDA numbers. The true (non-finance lease) debt is ~$34M, so with $10.3m in EBITDA this Q they are well under 1x levered. On an EBITDA multiple basis it trades at ~4x This ATH margin and EPS was notably achieved primarily through higher gross margin - their OpEx is still quite high and there do not seem to be any materials synergies coming through. Operating leverage here would boost EPS well above $2
1 · Reply
jParkz
jParkz Jun. 26 at 4:30 PM
News Article Kewaunee Scientific Corp. (NASDAQ: KEQU) Rises Sharply in 6/26 Early Trading Session https://marketwirenews.com/news-releases/kewaunee-scientific-corp-nasdaq-kequ-rises-sharply-i-6524485934250757.html $KEQU
0 · Reply
topstockalerts
topstockalerts Jun. 26 at 3:18 PM
Top Gainers PT2 $KEQU $LIVE $SRFM $BIAF $GWH
0 · Reply
Esau815
Esau815 Jun. 26 at 2:46 PM
$KEQU They had a great quarter. But lots of stuff that's opaque: 1. Will Hull and Gardner continue their stock sales? (Really guys? You sold stock in the mid 30's? Wouldn't a loan have made more sense if you were short cash? These were open market sales not 10b-5.) 2. Will that backlog continue to hold in light of Trump's evisceration of the scientific community? 3. Will cash flow continue to flow in to pay off what is now a fairly sizable chunk of debt to pay Nu Aire? (Not worried about sales leaseback debt.) 4. Mystery continues to be--how could Hull and Gardner sell stock in the 30's knowing that these sales were coming? You can't get in trouble with the SEC for holding your shares.
0 · Reply
topstockalerts
topstockalerts Jun. 26 at 2:20 PM
$KEQU primed for continuation.. ✅📈 Stay tuned bulls!!...👀--👀...
0 · Reply
Bruces4
Bruces4 Jun. 26 at 1:38 PM
$KEQU Annual sales aprx $300M. Trading NOW at $156M - about a .5 P/S ratio...
1 · Reply